Novel anticoagulants for stroke prevention in atrial fibrillation: Current clinical evidence and future developments

Journal of the American College of Cardiology

Volumn 56, Issue 25, 2010, Pages 2067-2076

  Schirmer, Stephan H ^a   Baumhkel, Magnus ^a   Neuberger, Hans Ruprecht ^a   Hohnloser, Stefan H ^b   Van Gelder, Isabelle C ^c,d   Lip, Gregory Y H ^e   Bhm, Michael ^a  

^a Klinik fur Innere Medizin III   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; ARGATROBAN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ECARIN; EDOXABAN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; IRBESARTAN; PROTEINASE ACTIVATED RECEPTOR; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; BLEEDING; BRAIN ISCHEMIA; CARDIAC PATIENT; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE III AS TOPIC; DRUGS, INVESTIGATIONAL; FACTOR XA; HUMANS; STROKE; THROMBIN;

EID: 78650034786     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.09.017     Document Type: Review

References (83)

1. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
2. W.M. Feinberg, J.L. Blackshear, A. Laupacis, R. Kronmal, and R.G. Hart Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications Arch Intern Med 155 1995 469 473
3. Y. Miyasaka, M.E. Barnes, and B.J. Gersh Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
4. P. Bernhardt, H. Schmidt, T. Sommer, B. Luderitz, and H. Omran Atrial fibrillationpatients at high risk for cerebral embolism Clin Res Cardiol 95 2006 148 153
5. K.M. Flegel, M.J. Shipley, and G. Rose Risk of stroke in non-rheumatic atrial fibrillation Lancet 1 1987 526 529
6. M. Hughes, and G.Y. Lip Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data Thromb Haemost 99 2008 295 304
7. G.Y. Lip Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis Thromb Haemost 100 2008 11 13
8. C. Marini, F. De Santis, and S. Sacco Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study Stroke 36 2005 1115 1119
9. H.-J. Lin, P.A. Wolf, and M. Kelly-Hayes Stroke severity in atrial fibrillation: the Framingham study Stroke 27 1996 1760 1764
10. M. Bhm, M. Thoenes, and H.R. Neuberger Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients Eur Heart J 30 2009 1364 1371
11. D. Lloyd-Jones, R. Adams, M. Carnethon American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 2009 e21 e181
12. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
13. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
14. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
15. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
16. S.J. Connolly, J. Pogue, J. Eikelboom ACTIVE W Investigators Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 2008 2029 2037
17. D.B. Matchar, G.P. Samsa, S.J. Cohen, E.Z. Oddone, and A.E. Jurgelski Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial Am J Med 113 2002 42 51
18. J. Mant, F.D. Hobbs, and K. Fletcher Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
19. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
20. K. Borensztajn, M.P. Peppelenbosch, and C.A. Spek Factor Xa: at the crossroads between coagulation and signaling in physiology and disease Trends Mol Med 14 2008 429 440
21. T.C. Sarich, M. Wolzt, and U.G. Eriksson Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects J Am Coll Cardiol 41 2003 557 564
22. Z. Xiao, and P. Theroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256
23. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate Thromb Haemost 98 2007 155 162
24. J.I. Weitz, M. Hudoba, D. Massel, J. Maraganore, and J. Hirsh Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Invest 86 1990 385 391
25. C.W. Francis, S.D. Berkowitz, P.C. Comp EXULT A Study Group Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 2003 1703 1712
26. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
27. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
28. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
29. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295 (Pubitemid 351508116)
30. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilatea novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
31. B.I. Eriksson, O.E. Dahl, and N. Rosencher Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956 (Pubitemid 47393577)
32. M.H. Huo, B.I. Eriksson, and O.E. Dahl Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomized trial (abstr) Haematologica Suppl 2 2010 95
33. B.I. Eriksson, O.E. Dahl, and N. Rosencher Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
34. J.S. Ginsberg, B.L. Davidson, and P.C. Comp Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
35. R.J. Friedman, O.E. Dahl, N. Rosencher RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials Thromb Res 126 2010 175 182
36. C.A. Salazar, G. Malaga, and G. Malasquez Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement Cochrane Database Syst Rev 4 2010 CD005981
37. S. Schulman, C. Kearon, A.K. Kakkar RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
38. M.D. Ezekowitz, P.A. Reilly, and G. Nehmiz Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol 100 2007 1419 1426
39. S.J. Connolly, M.D. Ezekowitz, S. Yusuf RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
40. S.H. Schirmer, A.M. van der Laan, M. Bhm, and F. Mahfoud Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more Clin Res Cardiol 98 2009 691 699
41. J. Oldgren, M. Alings, and H. Darius Dabigatran versus warfarin in atrial fibrillation in patients with low, moderate and high CHADS2 score: a RE-LY subgroupd analysis (abstr) J Am Coll Cardiol 55 Suppl A 2010 A1 E2
42. L. Wallentin, S. Yusuf, and M.D. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
43. M.J. Koti, A. Parekh, and S.J. Connolly Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion (abstr) J Am Coll Cardiol 55 Suppl A 2010 A4 E40
44. G.Y.H. Lip, K. Huber, and F. Andreotti Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summarya consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 31 2010 1311 1318
45. C. Jacobshagen, D. Westermann, C. Holubarsch, and M. Bhm Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more Clin Res Cardiol 99 2010 337 344
46. J.S. Healey, J. Eikelboom, and L. Wallentin Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study (abstr) J Am Coll Cardiol 55 Suppl A 2010 A4 E37
47. S.E. Wolowacz, N.S. Roskell, and J.M. Plumb Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Thromb Haemost 103 2010 360 371
48. G.Y.H. Lip, L.H. Rasmussen, and S.B. Olsson Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists Eur Heart J 30 2009 2897 2907
49. S.B. Olsson, L.H. Rasmussen, and A. Tveit Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation Thromb Haemost 103 2010 604 612
50. G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888
51. M.S. Sabatine, E.M. Antman, and P. Widimsky Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet 374 2009 787 795
52. J.M. Walenga, M. Prechel, and W.P. Jeske Rivaroxabanan oral, direct Factor Xa inhibitorhas potential for the management of patients with heparin-induced thrombocytopenia Br J Haematol 143 2008 92 99
53. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxabanan oral, direct factor Xa inhibitorare not affected by aspirin J Clin Pharmacol 46 2006 981 990
54. B.I. Eriksson, L.C. Borris, and R.J. Friedman Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
55. A.K. Kakkar, B. Brenner, and O.E. Dahl Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 33
56. M.R. Lassen, W. Ageno, and L.C. Borris Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
57. A.G. Turpie, M.R. Lassen, and B.L. Davidson Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
58. H.R. Buller Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism: the Einstein-Extension study (abstr) Blood 2009 114
59. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347 e1
60. H.R. Bller, J.L. Halperin, H. Bounameaux, and M. Prins Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants J Thromb Haemost 6 2008 227 229
61. J.L. Mega, E. Braunwald, and S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
62. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
63. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
64. J.H. Alexander, R.C. Becker, and D.L. Bhatt Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
65. R.D. Lopes, J.H. Alexander, and S.M. Al-Khatib Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
66. J.W. Eikelboom, M. O'Donnell, and S. Yusuf Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 159 2010 348 353 e1
67. Pfizer/Bristol-Myers Squibb AVERROES study of investigational agent apixaban closes early due to clear evidence of efficacy [Press release]. 2010 http://www.businesswire.com/news/bms/20100610006606/en/AVERROES-Study- Investigational-Agent-Apixaban-Closes-Early Accessed September 30, 2010
68. A.G. Turpie, K.A. Bauer, and B.L. Davidson A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) Thromb Haemost 101 2009 68 76
69. K. Ogata, J. Mendell-Harary, and M. Tachibana Clinical safety, rolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
70. B.I. Eriksson, A.G. Turpie, and M.R. Lassen Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty A dose finding study (ONYX-2) J Thromb Haemost 8 2010 714 721
71. G. Agnelli, S. Haas, J.S. Ginsberg, K.A. Krueger, A. Dmitrienko, and J.T. Brandt A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement J Thromb Haemost 5 2007 746 753 (Pubitemid 46563573)
72. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
73. M. Eto, C. Barandier, and L. Rathgeb Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting wnzyme-1 wxpression by sistinct pathways: role of Rho/ROCK and mitogen-activated protein kinase Circ Res 89 2001 583 590
74. X.-F. Ming, C. Barandier, and H. Viswambharan Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction Circulation 110 2004 3708 3714
75. D. Chen, A. Carpenter, and J. Abrahams Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo J Exp Med 205 2008 1739 1746
76. S. Inoue, K. Egashira, and W. Ni Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice Circulation 106 2002 2700 2706
77. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
78. S. Seehaus, K. Shahzad, and M. Kashif Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-C{beta}-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability Circulation 120 2009 774 784
79. X. Yin, J. Wright, T. Wall, and P. Grammas Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease Am J Pathol 176 2010 1600 1606
80. K. Martin, S. Weiss, and P. Metharom Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin Circ Res 105 2009 214 218
81. G.S. Bogatkevich, A. Ludwicka-Bradley, and R.M. Silver Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts Arthritis Rheum 60 2009 3455 3464
82. D. Chen, J.M. Abrahams, L.M. Smith, J.H. McVey, R.I. Lechler, and A. Dorling Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors Blood 111 2008 4155 4164
83. K. Schror, E. Bretschneider, and K. Fischer Thrombin receptors in vascular smooth muscle cellsfunction and regulation by vasodilatory prostaglandins Thromb Haemost 103 2010 884 890